zwitterionic oral selective Nav1.7 inh. for pain

predicted QD dosing, completed Ph. I, discont.

PK optimization of prior scaffold

J. Med. Chem., Mar. 8, 2021

Genentech, South San Francisco, CA / Xenon

Structure of GDC-0310

The Genentech Nav1.7 inhibitor (GDC-0310) is a oral Ph. I clinical candidate for pain. Nav1.7 has been a hot target for pain, and we previously highlighted a Nav1.7 inhibitor…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: